Colorectal Metastatic - EGFR
Published: Fri Oct 7, 2011 Updated:Sat Oct 15, 2011
-
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Douillard JY et al; October 4, 2010; JCO.2009.27.4860
-
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
E Diaz-Rubio et al; January 10, 2012; The Oncologist 2012; 17:15-25
-
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
KM Tveit et al; April 12, 2012; JCO.2011.38.0915
-
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
M Peeters et al; October 4, 2010, doi: 10.1200/JCO.2009.27.6055
-
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies.
F Loupakis et al, Cancer. Aug 25, 2011;doi: 10.1002/cncr.26460. [Epub ahead of print]
-
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
TS Maughan et al, Lancet. June 4, 2011; DOI:10.1016/S0140- 6736(11)60613-2
-
The CRYSTAL Study: Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
E Van Cutsem et al, JCO. April 18, 2011; 29(15):2011-2019
-
The PRIME Study: Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer
J-Y Douillard et al, JCO. Published online before print October 4, 2010
-
The CRYSTAL Study: Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
E Van Cutsem et al, NEJM. Apr 02 2009; 360(14):1408-17
-
The OPUS Study: Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
C Bokemeyer et al, JCO. Feb 10 2009; 27(5):663-671
-
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
CS Karapetis et al, NEJM. Oct 23 2008; 359(17):1757-65
-
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
RG Amado et al, JCO. Apr 01 2008; 26(10):1626-34
